Achieving Value in Cancer Care

Video

This video explores the value proposition in cancer care, with practical considerations for reducing costs at both the hospital and physician level while maintaining optimal care for cancer patients.

With the rising costs of targeted agents, immunotherapies, and combination treatment strategies, creating value while maintaining optimal care for cancer patients is of critical importance.

In this video, Daniel R. Gomez, MD, of MD Anderson Cancer Center, discusses the value proposition in cancer care, with practical considerations for reducing costs at both the hospital and physician level without sacrificing high levels of care to patients.

Gomez gave a presentation on this topic at the 2017 Multidisciplinary Thoracic Cancers Symposium, held March 16–18 in San Francisco.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
2 experts in this video
Related Content